<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03858478</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 055- FAST</org_study_id>
    <nct_id>NCT03858478</nct_id>
  </id_info>
  <brief_title>Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST</brief_title>
  <acronym>FAST</acronym>
  <official_title>Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of antiretroviral treatment adherence using determination of Bictegravir,
      Emtricitabine and Tenofovir with new HIV patients in France
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patient treated at the first clinical contact

        -  18 sites (hospitals) in France

        -  Treatment during 48 weeks with principal objective at W24 (plasma HIV-RNA &lt; 50
           copies/ml)

        -  Evaluation of antiretroviral treatment adherence using determination of Bictegravir,
           Emtricitabine and Tenofovir in hair sample
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot study, single arm, multicentric, national</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To achieve virological suppression (plasma HIV-RNA &lt; 50 copies/ml) at Month 6 (M6)on study treatment with a first-line treatment with TAF / FTC/ BIC initiated at the first clinical contact (Snapshot method)</measure>
    <time_frame>virological suppression at Month 6 (M6)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of participants with a false positive HIV screening test (i.e. a first positive test that has not been confirmed)</measure>
    <time_frame>DAY 0 (D0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participants with plasma HIV-RNA &lt; 50 copies/ml</measure>
    <time_frame>Month 1 (M1), Month 3 (M3), Month 6 (M6), Month 9 (M9), Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in CD4 T cell count</measure>
    <time_frame>between DAY 0 (D0) and Month 3 (M3), Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in CD4/CD8 ratio</measure>
    <time_frame>between DAY 0 (D0) and Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participants requiring discontinuation/modification of TAF/FTC/Bictegravir due to (i) Baseline resistance to one of the study drugs, (ii) adverse events leading to study treatment discontinuation/Modification</measure>
    <time_frame>Between DAY 0 (D0) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participants experiencing a grade 3-4 adverse event (related or not related to study treatment)</measure>
    <time_frame>Between DAY 0 (D0) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participants with protocol defined virological failure (plasma HIV-RNA &gt; 400 copies/ml at Week 12 confirmed on a second sample drawn 15-21 days later, or two consecutive plasma HIV-RNA &gt; 50 copies/ml within 15-21 days as of Week 24)</measure>
    <time_frame>Between Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participants harboring a virus developing resistance-associated mutations at the time of protocol-defined virological failure</measure>
    <time_frame>Between Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of comedications used during the 12-months study period</measure>
    <time_frame>Between DAY 0 (D0) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adherence to study treatment evaluated by drug concentrations measurement in hair</measure>
    <time_frame>Month 1 (M1), Month 3 (M3), Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participants lost to follow-up throughout the 12-months study period (LFU = having missed more than two consecutive visits except for W24 and W48 visit)</measure>
    <time_frame>Between DAY 0 (D0) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>participants' acceptability of immediate antiretroviral initiation treatment (self-assessed auto-questionnaires</measure>
    <time_frame>At Day 0 (D0), Month 3 (M3), Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adherence to study treatment evaluated by (i) self-assessed auto-questionnaires (4-day recall),</measure>
    <time_frame>Month 1 (M1), Month 3 (M3), Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adherence to study treatment evaluated by drug concentrations measurement in plasma</measure>
    <time_frame>Month 1 (M1), Month 3 (M3), Month 6 (M6) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of comedications used during the 12-months study period</measure>
    <time_frame>Between DAY 0 (D0) and Month 12 (M12)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>HIV Seropositivity</condition>
  <arm_group>
    <arm_group_label>Biktarvy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one tablet of BIKTARVY including [TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) ] one tablet once a day for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biktarvy arm</intervention_name>
    <description>BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)</description>
    <arm_group_label>Biktarvy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  newly diagnosed HIV-infected individual evidenced by any of the following tests: (i)
             positive self-test, (ii) positive HIV Rapid antibody test, (iii) positive HIV
             immunoassay (ELISA 4th generation) test

          -  antiretroviral-treatment naive

          -  negative urine pregnancy test for women of childbearing potential and willing to use
             effective contraception (mechanical or medicamental)

          -  willing to sign an informed written consent-

          -  regular health insurance

          -  willing to provide two distinct contact information (telephone number and/or email) in
             order to be easily reached if needed between Day 0 and Day 7

        Exclusion Criteria:

          -  clinical symptoms suggestive of opportunistic infections

          -  participant not willing to provide two distinct contact information

          -  a woman who is pregnant or breast-feeding or planning to become pregnant during the
             expected study period.

          -  Co-medication with deleterious interaction with study treatment (eg enzyme inducer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AIDA AB BENALYCHERIF</last_name>
    <phone>+33.1.40.25.63.65</phone>
    <email>aida.beanlycherif@imea.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>KARINE KA AMAT</last_name>
    <phone>+33.1.40.25.63.52</phone>
    <email>karine.amat@imea.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Zobda Quitman</name>
      <address>
        <city>Fort-de-france</city>
        <state>Martinique</state>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>André AC CABIE, PhD</last_name>
      <phone>+33.5.96.55.23.01</phone>
      <email>andre.cabie@chu-fort-de-france.fr</email>
    </contact>
    <investigator>
      <last_name>André AC CABIE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin - Service de Médecine Interne et Maladies Infectieuses</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SEVERINE SL LE PUIL</last_name>
      <phone>33.5.56.79.55.36</phone>
      <email>severine.lepuil@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>I</last_name>
    </contact_backup>
    <investigator>
      <last_name>Didier NEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte de Nacre - Service des Maladies Infectieuses</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud RV VERDON, MD, PhD</last_name>
      <phone>33.2.31.06.47.09</phone>
      <email>verdon-r@chu-caen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pascale PG GOUBIN</last_name>
      <phone>33.2.31.06.47.09</phone>
      <email>goubin-p@chu-caen.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Renaud VERDON, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Jacques PARIENTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie DARGERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nouara NA AGHER</last_name>
      <phone>+33.1.61.69.77.04</phone>
      <email>nouara.agher@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Amélie AC CHABROL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Service d'Immunologie Clinique</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Daniel JDL LELIEVRE, MD</last_name>
      <phone>33.1.49.81.24.05</phone>
      <email>jean-daniel.lelievre@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Daniel LELIEVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Francois Mitterrand</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine SG GOHIER</last_name>
      <phone>+33.3.80.29.36.31</phone>
      <email>sandrine.gohier@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel LP PIROTH, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Raymond Poincare</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgane HB MARCOU</last_name>
      <phone>+33.1.47.10.46.65</phone>
      <email>morgane.marcou@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre PT DE TRUCHIS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte-Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline CD DEBREUX</last_name>
      <phone>+33.4.91.74.61.63</phone>
      <email>caroline.debreux@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle IM POIZOT-MARTIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac - Service de Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques REYNES, MD, PhD</last_name>
      <phone>33.4.67.33.77.25</phone>
      <email>j-reynes@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christine TRAMONI</last_name>
      <phone>33.4.67.33.77.26</phone>
      <email>c-tramoni@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques REYNES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L'ARCHET</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ghaleb GZ ZOUZOU</last_name>
      <phone>+33 4 92 03 58 24</phone>
      <email>zouzou.g@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>ALISSA AN NAQVI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian CT TRAN</last_name>
      <phone>+33.1.49.28.24.86</phone>
      <email>christian.tran@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Karine KL LACOMBE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima FT TOUAM</last_name>
      <phone>+33.1.44.49.40.28</phone>
      <email>fatima.touam@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Claudine CD DUVIVIER, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zélie ZJ JULIA</last_name>
      <phone>+33.1.40.25.70.57</phone>
      <email>zelie.julia@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yazdan YY YAZDANPANAH, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne AA ADDA</last_name>
      <phone>+33.1.56.01.74.36</phone>
      <email>anne.adda@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles GP PIALOUX, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina AF FADLI</last_name>
      <phone>+33.1.46.25.11.73</phone>
      <email>a.fadli@hopital.foch.org</email>
    </contact>
    <investigator>
      <last_name>David DZ ZUCMAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Gustave Dron</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie SV VANDAMME</last_name>
      <email>svandamme@ch-tourcoing.fr</email>
    </contact>
    <investigator>
      <last_name>Faiza FA AJANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier OB BOURGAULT</last_name>
      <phone>+33.2.47.47.37.14</phone>
      <email>o.bourgault@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Louis LB BERNARD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV, new diagnosis, Biktarvy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

